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Background: The Montpellier cancer institute phase II trial started in 2004 and evaluated the feasibility of
intraoperative radiotherapy (IORT) technique given as a sole radiation treatment for patients with an excellent
prognostic and very low recurrence risk.
Methods: Forty-two patients were included between 2004 and 2007. Inclusion criteria were patients ≥ 65 years old,
T0-T1, N0, ductal invasive unifocal carcinoma, free-margin > 2 mm. IORT was delivered using dedicated linear
accelerator. One fraction of 21 Gy was prescribed and specified at the 90% isodose using electrons. In vivo
dosimetry was performed for all patients. Primary end-point was the quality index. Secondary endpoints were
quality of life, local recurrences, cosmetic results, specific and overall survival.
Results: At inclusion, median age was 72 years (range, 66–80). Median tumor diameter was 10 mm. All patients received
the total prescribed dose. No acute grade 3 toxicities were observed. Late cosmetic results were good at 5 years despite
the poor agreement of accuracy assessment between patients and physicians. Four patients (9.5%) experienced a local
failure and underwent salvage mastectomy. The 5 year-disease free survival is 92.7% (range 79.1−97.6). All patients are still
alive with a median follow-up of 72 months (range 66–74).
Conclusion: Our results confirm with a long-term follow-up that exclusive partial breast IORT is feasible for early-breast
cancer in selected patients. IORT provides good late cosmetics results and should be considered as a safe and very
comfortable “one-step” treatment procedure. Nevertheless, patient assessments are essential for long-term quality results.Background
Breast-conserving surgery followed by a whole-breast
postoperative RT (WBRT) is widely considered to be the
current standard of care for patients with early breast
cancer. This treatment leads to an excellent local tumor
control with local recurrence rates around 6% after 10
years, particularly in the very-low risk subgroup [1]. This
classical 5–7 weeks WBRT is simple and safe in the large
majority of patients but may bring some local early and
late side effects. In addition, it is frequently inconvenient
for women, namely in the elderly, who sometimes prefer
to omit it assuming the risk of local recurrence. During* Correspondence: David.Azria@icm.unicancer.fr
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reproduction in any medium, provided the orthe last decades, through numerous observational series
and large clinical trials, more than 80% of the local re-
lapses occurred in the same quadrant in this clinical
situation [2].
On this basis, reducing both the treatment volume
and duration was considered to be an innovative ap-
proach and was developed under the name of acceler-
ated partial breast irradiation (APBI). Intraoperative
radiotherapy (IORT) is one of them that offers the ad-
vantages of an excellent delineation of the tumor bed
under visual control, a very good dose homogeneity, and
a high normal tissue sparing [3,4].
Alongside our IORT experience delivered as a boost
[5], we started in 2004 the RADELEC phase II trial
evaluating IORT as a sole treatment in very low-risk pa-
tients. We report here the long-term results of safety,
cosmesis, and carcinologic events.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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This study was conducted in accordance with the declar-
ation of Helsinki and the local institutional review board.
All patients provided written informed consent.Inclusion criteria
Between November 2004 and November 2007, 96
women accepted to participate in the RADELEC phase
II trial evaluating IORT delivered to the tumor bed as
exclusive radiotherapy. Inclusion criteria were T1N0M0
[6] unifocal ductal invasive carcinoma (biopsy-proven)
with positive (> 10%) estrogen receptors, non-metastatic
disease, and age ≥ 65 years old. No extensive intraductal
(EIC) or lymph vessel invasion had to be identified on pri-
mary biopsy.
Local evaluation (mammography and breast ultra-
sound) evaluated precisely the diameter of the tumor
(MRI was optional). Lobular tumors were excluded due
to the risk of multifocality. Neoadjuvant treatments were
not allowed before surgery.IORT procedure and postoperative therapies
The detailed procedure was described in a previous article
[7]. Briefly, IORT modalities included a dedicated linear
accelerator (Saturne 43, Varian, France) located centrally
between the six operating theaters. Lumpectomy was
performed with an incision centered on the tumor or
periareolar in outer or inner/medial lesions, respectively.
Tumor-free margins of at least 2 mm were assessed by
frozen sections. Axillary lymph node dissection was
performed using a sentinel lymph node procedure in all
cases. Nodes were analyzed by intraoperative imprint cy-
tology. The tissue surrounding the excision cavity was
then mobilized and approximated by sutures to bring it
into the radiotherapy planning target volume. The radi-
ation oncologist identified visually the tumor bed and, to-
gether with the surgeon, measured the depth of the tissue
to be irradiated. A semi-conductor detector (PTW) was
placed in the middle of the tumor cavity and fixed to
proceed to an in vivo dosimetry. The applicator tubes were
then placed under visual control. The entire tumor bed
was strictly encompassed customarily with a 20-mm mar-
gin using 40–60 mm diameter flat-ended brass applicators.
Complete skin sparing was verified in each case.
The treatment was delivered at using electrons with an
energy ranged between 6 and 9 MeV, in accordance with
the thickness of breast tissue to be treated. All patients
received 21 Gy, prescribed and specified at the depth of
the 90% isodose line, which was defined as the optimal
and maximal tolerated dose level [8].
In vivo dosimetry was performed in all patients. Fol-
lowing IORT, the incision was closed in the conventional
fashion by the surgeon.Patients were seen three weeks after IORT for the first
medical follow-up and were prescribed adjuvant treatment
according to our guidelines. Postmenopausal women who
were shown to have estrogen receptor and/or progester-
one receptor-positive tumors (ER and/or PR = 10% of the
tumor cells positive by an immunocytochemical assay)
were prescribed an aromatase inhibitor in front line or se-
quentially after two years of tamoxifen. No adjuvant
chemotherapy was initially planned in this setting i.e.
T1N0M0 and age ≥ 65 years old.
Long-term cosmetic assessment
Long term cosmetic results were yearly performed by
the surgeons and the radiation oncologists with clinical
exams, systematic photographs (two pictures with
frontal and profile views), and a local questionnaire
filled in independently by the patient and the physician.
We considered the breast shape and position, the areola
shape, and the presence or absence of telangiectasia.
Statistical analysis
This phase II trial was conducted using a two-stage
optimum Simon design with forty-two eligible patients re-
quired for evaluation of the primary endpoint defined as
IORT reproducibility using the quality index (QI) compar-
ing prescribed and the in vivo measured doses [7].
Data were summarized by frequency and percentage
for categorical variables, and by means, standard devia-
tions, median, and range for continuous variables.
Updated median follow-up was obtained with the re-
verse Kaplan-Meier method.
All survival events were measured from the day of sur-
gery to event (assessed by clinical exam, mammography,
or breast ultrasound). Disease-free survival (DFS; event
was locoregional/distant recurrence or death) and over-
all survival (OS; event was death) rates were estimated
according to the Kaplan-Meier method.
Cohen's kappa coefficient was used to measure inter-
rater agreement for qualitative items [9]. A κ less than 0
is a disagreement, from 0.0 to 0.20 is a very poor agree-
ment, from 0.21 to 0.40 is a poor agreement, from 0.41
to 0.60 is a moderate agreement, from 0.61 to 0.80 is a
strong agreement, and from 0.81 to 1.00 is an almost
perfect agreement.
Analyses were performed using STATA 11.0.
Results
IORT reproducibility as a primary end-point
Among the 42 patients, 36 procedures were assessable
and 35 were measured as acceptable according to the
primary endpoint (97%). The median measured dose was
23 Gy (range, 19.6–26.5 Gy), with a high concordance
with the prescribed dose (21 Gy at the 90% isodose, cor-
responding to 23 Gy at the 100% level).
Lemanski et al. Radiation Oncology 2013, 8:191 Page 3 of 9
http://www.ro-journal.com/content/8/1/191Long-term toxicities and carcinologic events
Among the 94 patients who accepted to participate
in this trial and signed the informed consent before
the surgical procedure, 11 patients were treated by
IORT but were secondary excluded of the final ana-
lysis due to the definitive pathologic report. The rea-
sons of non IORT delivery were detailed for 41
patients in Lemanski et al. [7]. Finally, 42 patients
were included in the RADELEC trial according to the
study criteria.
Clinical breast parameters and tumor characteristics
were reported before [7]. Briefly, the median tumor
size was 10 mm (range 3–19), SBR I-II grade
concerned 36 tumors (86%), and 100% of the tumors
expressed estrogen receptors. According to our na-
tional guidelines, no chemotherapy was indicated for
these T1N0 hormone-relevant tumors and adjuvant
hormonal treatment was started within the first




3 years post-RT, n=39
4 years post-RT, n=39
5 years post-RT, n=40
Non eligible patients*,n=11
Untreated**, n=41
Figure 1 Consort diagram. * Eleven 11 patients received IORT but definit
positive sentinel nodes were found on the definitive pathology reports for
found in 1 patient; and margins IORT in breast cancer were <2 mm for 2 p
mastectomy. After IORT, the 11 patients did not receive any additional exte
reasons for nondelivery of IORT (n=41) were: (i) pT/pN restaging during the
(n = 6), (iii) machine disorder (n = 3), (iv) anesthesia complications (n = 2),No immediate severe side-effect was observed during the
IORT procedure. At discharge, three acute wound complica-
tions, one infection, five haematoma, and six moderate local
pains. None of them necessitated secondary intervention [7].
All included patients are still alive with a median
follow-up of 72 months (range 66–74, Figure 1). The
5-year-disease free survival is 92.7% (range 79.1−97.6).
Among the 42 included patients, four experienced a
local event. Three were defined as ipsilateral breast
tumor relapses (IBRT) according to the Royal Marsden
criteria [10] i.e. in the same quadrant as the primary
tumor, with the same histology and similar or higher
grade. These true relapses occurred within the initial
tumor bed but relatively delayed after the IORT proced-
ure (25, 54, and 60 months). The two first were 18 and
2 mm ductal unifocal carcinomas. The latter one was
considered as a more aggressive relapse identified by






Follow-up not done n=3
4 years post-RT
Follow-up not done n=3
5 years post-RT
Follow-up not done n=2
ive pathology results did not strictly follow the inclusion criteria:
6 patients; lobular carcinoma was found for 2 patients; bifocality was
atients. These two patients with close margins underwent radical
rnal RT and were followed according to the protocol. **The main
IORT pathology assessment (n =29), (ii) operative room availability
(v) informed consent withdrawal (n= 1).
Figure 2 Photographies of patient #1 with 60 months
of follow-up.
Figure 4 Photographies of patient #3 with 60 months
of follow-up.
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ductal carcinoma located in another quadrant and diag-
nosed 3 months after the surgery. The RADELEC scien-
tific committee considered this event as a second primary
tumor omitted during the preoperative staging (staged
only by ultrasound).
These four patients underwent standard salvage mast-
ectomy and all restarted a new hormonal treatment for
five years more. None received any chemotherapy.
The eleven patients who received IORT but excluded
after the definitive pathology results were also followed
within the time frame. None of them presented a local
recurrence and all are still alive without any disease.
Long term cosmetic assessment
Post-treatment mammograms showed characteristic pic-
tures of severe cytosteatonecrosis in 30 patients (71%) cor-
responding to a palpable mass within the IORT area for 17Figure 3 Photographies of patient #2 with 60 months
of follow-up.patients (40%). These structural changes in the tumor bed
complicated the evaluation of mammograms within the
first two years of follow-up. Two patients required non-
routine procedures leading to a biopsy for pathological
control. Both of them had outside institution exams.
Ten patients (24 %) reported late grade 1 breast pain.
One patient experienced a rib fracture 14 months after
the IORT procedure. Globally, 41 among the 42 treated
patients (98%) disclaimed a totally satisfaction of IORT
and would recommend the procedure.
The 5 year-cosmetic evaluation, including clinical exam-
ination and systematic photographs reviewed by 2 physi-
cians showed good to excellent results and are presented
for 4 patients in Figures 2, 3, 4 and 5. These photographs
showed excellent results whatever the size of the breast
(Figure 2, 3, 5). For inferior tumors, scar retraction seemsFigure 5 Photographies of patient #4 with 60 months
of follow-up.
Table 1 Late cosmetic results from patient evaluation
24 m (n=39) 48 m (n=39) 60 m (n=40)
N % N % N %
32 82.1 28 71.8 28 70.0
Breast size
No difference 20 62.5 20 71.4 20 71.4
Small difference 10 31.3 5 17.9 4 14.3
Middle difference 1 3.1 2 7.1 3 10.7
High difference 1 3.1 1 3.6 1 3.6
Breast shape
No difference 17 53.1 17 60.7 15 53.6
Small difference 13 40.6 8 28.6 10 35.7
Middle difference 1 3.1 2 7.1 2 7.1
High difference 1 3.1 1 3.6 1 3.6
Nipple position
No difference 24 75.0 27 96.4 26 92.9
Small difference 5 15.6 1 3.6 1 3.6
Middle difference 1 3.1 0 0
High difference 1 3.1 0 1 3.6
Not evaluable 1 3.1 0 0
Nipple shape
No difference 27 84.4 27 96.4 26 92.9
Small difference 4 12.5 0 1 3.6
Middle difference 1 3.1 1 3.6 0
High difference 0 0 1 3.6
Skin color
No difference 28 87.5 25 92.6 28 100.0
Small difference 3 9.4 2 7.4 0
Not evaluable 1 3.1 0 0
Scar appearance
Soft 16 50.0 14 50.0 14 50.0
Visible, does not affect the result 10 31.3 10 35.7 9 32.1
Visible, slightly affects the result 5 15.6 4 14.3 4 14.3
Visible, significantly affects the result 1 3.1 0 1 3.6
Telangiectasia
Not visible 30 96.8 26 96.3 27 100.0
Rare : <1 / cm2 1 3.2 1 3.7 0
Global Cosmetic Result
Excellent 12 38.7 12 42.9 6 21.4
Good 15 48.4 10 35.7 18 64.3
Fair 3 9.7 5 17.9 2 7.1
Bad 1 3.2 1 3.6 1 3.6
Not evaluable 0 0 1 3.6
m months, N number.
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Table 2 Late cosmetic results from physician evaluation
24 m (n=39) 48 m (n=39) 60 m (n=40)
N % N % N %
32 82.1 27 69.2 29 72.5
Breast size
No difference 22 68.8 13 48.2 12 41.4
Small difference 8 25.0 11 40.7 12 41.4
Middle difference 1 3.1 3 11.1 4 13.8
High difference 1 3.1 0 1 3.4
Breast shape
No difference 19 59.4 12 44.4 9 31.0
Small difference 9 28.1 10 37.0 17 58.6
Middle difference 3 9.4 4 14.8 2 6.9
High difference 1 3.1 1 3.7 1 3.5
Nipple position
No difference 24 77.4 18 66.7 17 58.6
Small difference 5 16.1 8 29.6 11 37.9
Middle difference 1 3.2 1 3.7 1 3.4
High difference 1 3.2 0 0
Nipple shape
No difference 28 87.5 23 85.2 24 82.8
Small difference 3 9.4 4 14.8 4 13.8
Middle difference 0 0 1 3.4
High difference 1 3.1 0 0
Skin color
No difference 31 96.9 26 96.3 27 93.1
Small difference 1 3.1 1 3.7 2 6.9
Scar appearance
Soft 17 53.1 12 44.4 12 41.4
Visible, does not affect the result 12 37.5 10 37.0 14 48.3
Visible, slightly affects the result 3 9.4 5 18.5 3 10.3
Visible, significantly affects the result 0 0 0
Telangiectasia
Not visible 32 100.0 27 100.0 28 100.0
Global cosmetic result
Excellent 16 50.0 15 57.7 13 48.2
Good 13 40.6 6 23.1 12 44.4
Fair 2 6.3 5 19.2 1 3.7
Bad 1 3.1 0 1 3.7
m months, N number.
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to the IORT procedure. The 1, 2, 3, 4, and 5-year cosmetic
results were auto-evaluated by patients and by physicians
with 97.5% compliance. The results were good and are de-
tailed in Tables 1 and 2. Overall, a poor agreement was ob-
served between patients and physicians about breast size,
nipple position, and scar appearance at all evaluation time.In addition, a very poor agreement was observed between
patients and physicians about telangiectasia and global cos-
metic result whatever the time of evaluation. Regarding
breast shape, we observed a poor agreement, a disagree-
ment, and a very poor agreement at 24, 48, and 60 months,
respectively. A moderate agreement was observed about
nipple shape at 24 months (Table 3). After pooling variables
Table 3 Inter-rater agreement (patients and physicians): kappa coefficient
24 m (n=39) p 48 m (n=39) p 60 m (n=39) p
Breast size 0.22 0.063 0.29 0.009 0.19 0.034
Breast shape 0.37 0.003 −0.05 0.642 0.12 0.157
Nipple position 0.12 0.168 0.14 0.062 0.10 0.111
Nipple shape 0.44 0.001 −0.03 0.664 0.04 0.340
Skin color 0.37 0.001 −0.04 0.635 −0.02 0.609
Scar appearance 0.29 0.016 0.10 0.236 0.29 0.011
Telangiectasia 0.00 - 0.00 - 0.00 -
Global cosmetic result 0.09 0.23 0.08 0.26 0.04 0.355
m months, n number.
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difference), the agreement Kappa coefficient is improved
for breast size at 24 and 60 months (0.46 and 0.60, respect-
ively). For breast shape, we observed a strong agreement at
24 and 60 months (0.63 for both) and a perfect agreement
for nipple position and nipple shape at 60 months.
Discussion
The updated publication of the collaborative meta-
analyses based on individual patient data confirmed that
WBRT halves similarly local recurrence rates in the dif-
ferent subgroups of patients and reduces the breast can-
cer death rate by about a sixth [1].
The need of WBRT was however debated since the pub-
lication of the CALGB 9343 trial estimating a low risk of
recurrence after conservative surgery in patients older
than 70 years presenting HR+ small tumors and only adju-
vant tamoxifen as adjuvant treatment [11]. These results
were updated at the annual meeting of the American soci-
ety of clinical oncology (ASCO) in 2010 and showed an in-
crease risk of local recurrence when adjuvant radiotherapy
was avoided. At a median follow-up of 10.5 years, 98% of
the radiation group and 92% of the tamoxifen-only group
were recurrence-free confirming the local risk of avoiding
adjuvant irradiation. In addition, the results of the
NSABP-21 [12] confirmed that the absolute risk of in-
breast recurrences of primary small tumors less than 1 cm
is not low enough to spare patients the need for WBRT.
Nevertheless, the standard of 5 to 6 weeks WBRT is no
longer the optimized strategy as it appears long and bind-
ing in this clinical situation. Indeed, the concept of accel-
erated whole-breast irradiation recently showed a risk of
local recurrences at 10 years of 6.7% among the 612
women assigned to standard irradiation as compared with
6.2% among the 622 women treated in 3 weeks [13]. At
the San Antonio Breast Cancer Symposium 2012, the
START B trial [14] was updated by Yarnold et al. and con-
firmed 5.5% and 4.3% of local recurrences at 10 years in
the standard and accelerated WBRT, respectively.
Considering that 80% of the local breast recurrences
occur within the tumor bed [15], other strategiesattempted to reduce the irradiated volume when accelerat-
ing the overall treatment time [16]. IORT procedure rep-
resents one of the possibilities offering a one-fraction
treatment in a limited volume during the primary surgery.
Our results confirmed with a long-term follow-up that ex-
clusive partial breast using IORT is feasible for early-
breast cancer with an absolute risk of carcinologic events
extremely low in much selected patients, namely in the
elderly. In that condition, using IORT for partial irradi-
ation with a 21-Gy fraction has the major and unique ad-
vantage of a “one-shot” procedure including surgery and
radiotherapy at the same time. Extending the duration of
surgery, from 20 to 50 minutes, permits to avoid 5 to 6 tir-
ing weeks of external radiotherapy, one of the reasons that
encourage patients to decline adjuvant radiotherapy or ask
for a mastectomy [17]. This argument is reinforced by the
proportion of the patients receiving the recommended ad-
juvant radiotherapy, less than 75% after seventy and even
less than 50% after eighty [18]. IORT may therefore repre-
sent an alternative considering the shortness and simpli-
city of the technique providing that this treatment is done
in expert hands.
Our updated results confirm with a long-term follow-
up that IORT, as an accelerated partial breast irradi-
ation technique, is suitable for selected patients and
could be a better compromise regarding tamoxifen
alone in adjuvant setting. However, the local recurrence
rates at 6 years, for this very favorable group of pa-
tients, seems quite high (9%), especially given the fact
that this subgroup of patients with indolent disease will
continue to recur in the next 10 and 15 years, for
whom rates of 6% at 10 years have been approximated.
Therefore, longer follow-up is needed to draw mean-
ingful conclusions.
Alongside our experience in IORT delivered as a boost
[4,5], we decided many years ago to extend this concept
to a specific very low-risk population (i.e. age ≥ 65 years
old, tumor size < 2 cm, non-lobular carcinoma and es-
trogen receptor positivity) for a unique and exclusive
treatment. We excluded BRCA1 or 2 carriers and exten-
sive in situ carcinoma. Since then, the American and
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(ASTRO and ESTRO, respectively) provided a consensus
statement for the use of accelerated partial breast irradi-
ation based on current published evidence and com-
pleted by expert opinion [19,20]. The patient selection in
the present study is perfectly concordant to these con-
sensuses and reinforces the necessity to respect all the
stringent criteria for further studies [21].
The choice of electrons for this partial breast radiother-
apy was based on our local experience in this technique
[4,5]. We showed that electrons allow an homogenous
dose, spare the skin and give time to surgeons for a post-
resection reconstruction of the cavity leading to very good
cosmetic results. Orecchia et al. presented the 5-year local
recurrence rate of patients included in the ELIOT trial
(electrons’ technique) at the last World Congress of
Brachytherapy in May 2012. The authors observed 3.6% of
local recurrence but longer follow-up is warranted to draw
definitive conclusions.
Recently, the TARGIT-A trial [22] was published
comparing standard WBRT to a single 20-Gy fraction
delivered intraoperatively but with a 50-kV system. The
4-year local relapse rates were not inferior in the IORT
arm (0.95 and 1.20% in the WBRT and IORT arms, re-
spectively). Mature results were presented at the last San
Antonio Breast Cancer Symposium 2012. The investigators
continued inclusions after the first publication (from 2232
to 3451 patients) that renders difficult long-term results.
The 5-year risks for local recurrence in the conserved
breast for TARGIT vs WBRT were 3.3% (95% CI 2.1-5.1) vs
1.3% (95% CI 0.7-2.5). Nevertheless, TARGIT had similar
results to WBRT 2.1% (1.1-4.2) vs 1.1% (0.5-2.5) in the pre-
pathology subgroup (concomitant surgery and TARGIT)
that reinforces the idea that delayed procedure by
reopening the wound has to be abandoned. Final data are
still pending for publication.
As local recurrences may occur after a long delay, final
assessment of kV-IORT will be definitely valid after suf-
ficient follow-up from large international prospective
randomized trials.
Frozen section is, for sure, one limiting aspect of any
intraoperative procedure, as the definitive pathology re-
port may contradict the biopsy. This technique requires
therefore a very close involvement of the pathologist, the
surgeon, and the radiation oncologist.
Even if the cosmetic results were evaluated as good,
structural changes in the tumor bed after IORT may re-
quire a learning curve for the radiologist in order to avoid
iterative biopsies [23]. The patient assessments seem ex-
tremely important before considering this technique as a
standard in daily practice. The use of 50-kV IORT will re-
duce the risk of late fibrosis and cytosteatonecrosis as the
need of dissection is highly less compared to IORT with
electrons (71% in the current trial). Indeed, the sphere ofIntrabeam fill in the surgical area whereas the tissue sur-
rounding the excision cavity is mo1bilized and approxi-
mated by sutures to bring it into the RT planning target
volume with electrons.
In contrast, IORT has several advantages and some
teams [24] emphasize that using IORT for adjuvant
breast radiotherapy may reduce the estimate of second-
cancer risk. Compared to classical external WBRT or
accelerated partial breast external irradiation, this tech-
nique delivers the lowest dose to the controlateral
breast, homo-, and controlateral lungs and spine.
Finally, IORT reduces the cost of adjuvant breast
radiotherapy and a medico-economic prospective study
is still ongoing in France to evaluate the impact of this
treatment on healthcare resources and public health.
Conclusions
In conclusion, our results confirm that IORT given as a
sole treatment during breast-conserving surgery is a reli-
able alternative to conventional postoperative fractionated
radiation. This one-stop treatment reduces patient effort
and limits the use of health care resources. It could be
considered as a standard in a selected population with
very-low risk of local recurrence but performed by multi-
disciplinary expert hands. Patients’ assessments strongly
improve long term evaluation of this technique.
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